Initiate Antihypertensive Treatment if Blood Pressure Remains Uncontrolled
STEP 1 — Gather Information
Measure seated and standing blood pressure, review current fludrocortisone dose and timing, assess for symptoms of hypertension (headache, visual changes) and signs of volume status (edema, orthostatic hypotension), check serum electrolytes (Na+, K+) and renal function.
STEP 2 — Rule In / Rule Out
Is blood pressure persistently elevated (e.g., systolic ≥140 mmHg or diastolic ≥90 mmHg on multiple readings) after a trial of fludrocortisone dose reduction? If yes, rule in uncontrolled hypertension; if no, rule out and continue current management.
STEP 3 — Classify or Stratify
Assess volume status: if patient shows signs of euvolemia (no edema, normal orthostatic vitals) and electrolytes are not suggestive of mineralocorticoid excess (normal K+), classify as hypertension likely due to fludrocortisone sensitivity requiring antihypertensive addition.
STEP 4 — Decide
Initiate an antihypertensive agent (e.g., ACE inhibitor or calcium channel blocker) while continuing the current fludrocortisone dose; avoid diuretics and aldosterone antagonists.
Clinical Guardrails / Mimics / Pitfalls
Do not discontinue fludrocortisone abruptly to avoid adrenal crisis; avoid spironolactone or eplerenone due to risk of hyperkalemia; avoid loop or thiazide diuretics that may worsen hyponatremia or precipitate adrenal insufficiency; monitor blood pressure and electrolytes within 1–2 weeks of starting antihypertensive.
Concrete Clinical Example
A 45-year-old woman on fludrocortisone 100 µg daily develops hypertension (BP 152/94) after dose reduction to 50 µg for suspected over-replacement; she has no edema, normal orthostatic vitals, and serum K+ 4.2 mmol/L. An ACE inhibitor is started and fludrocortisone is continued at 50 µg; BP improves to 128/78 mmHg at follow-up.
Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710